Valneva (NASDAQ:VALN) Shares Up 6.1%

Valneva SE (NASDAQ:VALN)’s stock price shot up 6.1% during trading on Thursday . The stock traded as high as $8.22 and last traded at $8.22. 1,859 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 9,146 shares. The stock had previously closed at $7.75.

Analyst Ratings Changes

Several brokerages recently commented on VALN. Guggenheim dropped their price objective on shares of Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, March 22nd. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Valneva in a research note on Thursday, March 21st.

Valneva Stock Down 6.3 %

The company’s 50 day moving average price is $7.67 and its 200-day moving average price is $9.62. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.37 and a current ratio of 1.65.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.70). The business had revenue of $45.12 million for the quarter, compared to the consensus estimate of $45.06 million. Valneva had a negative net margin of 65.99% and a negative return on equity of 59.48%. On average, research analysts predict that Valneva SE will post 0.11 EPS for the current year.

Institutional Investors Weigh In On Valneva

Large investors have recently modified their holdings of the company. UBS Group AG acquired a new stake in shares of Valneva during the second quarter worth $31,000. Bank of America Corp DE acquired a new stake in shares of Valneva during the first quarter worth $858,000. Finally, Jane Street Group LLC increased its position in shares of Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after buying an additional 7,664 shares during the period. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.